Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily sachet ease your IBS? new trial tests skal pro

NCT ID NCT06271538

Symptom relief Sponsor: EP Plus Group Sdn Bhd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests whether a daily dose of Skal Pro—a mix of a friendly bacteria (Lactobacillus plantarum 299v) and a prebiotic fiber—can reduce IBS symptoms like belly pain, bloating, and irregular bowel movements. Sixty adults with IBS will receive either the supplement or a dummy sachet for several weeks. Researchers will track changes in symptom severity, stool form, quality of life, and mood to see if the supplement offers real relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Skal Pro (Lactobacillus plantarum 299v and galacto-oligosaccharides)
What this could lead to
If it works, this could offer a natural, over-the-counter option to help manage IBS symptoms like belly pain, bloating, and irregular stools.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The placebo effect is strong in IBS studies, and the supplement may not outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

57 people

The number who actually took part.

Started

Oct 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * IBS diagnosed using the Rome IV criteria * Age above 18 years old and any gender * Any subtypes of IBS (diarrhea, constipation or mixed) Exclusion Criteria: * Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer) * Was prescribed antibiotic (s) within the past one month * Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy * Presence of bowel malignancy * Diagnosis of bowel infection within the past one month * Previous abdominal surgeries * Patients with overt psychiatric illnesses including schizophrenia and manic disorders * A history of allergy to probiotic * Was prescribed probiotic (s) within the past one month * Was previously prescribed probiotic Skal Pro™ (LP299V™)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colonic disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colonic disorder Digestive System Diseases digestive system disorder disease functional colonic disease intestinal disorder irritable bowel syndrome Pathologic Processes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colonic disease Colonic diseases, functional Digestive system disease Disease Gastrointestinal diseases Intestinal disease Irritable bowel syndrome Pathologic processes

Contacts and locations

Locations

  • Hospital Universiti Sains Malaysia

    Kubang Kerian, Kelantan, 16150, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.